<?xml version="1.0" encoding="utf-8"?><!DOCTYPE article PUBLIC "-//ES//DTD journal article DTD version 5.0.2//EN//XML" "art502.dtd" [<!ENTITY gr1 SYSTEM "gr1" NDATA IMAGE><!ENTITY gr2a SYSTEM "gr2a" NDATA IMAGE><!ENTITY gr2bc SYSTEM "gr2bc" NDATA IMAGE><!ENTITY gr3 SYSTEM "gr3" NDATA IMAGE><!ENTITY gr4 SYSTEM "gr4" NDATA IMAGE>]><article docsubtype="sco" xml:lang="en"><ce:floats xmlns:ce="http://www.elsevier.com/xml/common/dtd"><ce:figure id="fig1"><ce:label>Fig. 1</ce:label><ce:caption><ce:simple-para>Platelet adhesion in the absence of exogenous agonists and secondary mediators. (A) Washed platelets (1<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup>8</ce:sup> platelets/ml) were suspended in Mg<ce:sup>2+</ce:sup>-free or Mg<ce:sup>2+</ce:sup> (1<ce:hsp sp="0.25"/>mM)-replete Tyrode’s buffer were adhered to fibrinogen (1<ce:hsp sp="0.25"/>mg/ml) coated 96-well plates. Platelets were incubated for 15<ce:hsp sp="0.25"/>min at 37<ce:hsp sp="0.25"/>°C in the presence of apyrase (1U/ml), indomethacin (10<ce:hsp sp="0.25"/>μM), and RGDS (2<ce:hsp sp="0.25"/>mM) as indicated. Adhesion was measured spectrophotometrically as described in experimental procedures. Results are presented as means<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>S.E.M. of five independent experiments each performed in triplicate. (<ce:sup loc="pre">∗∗</ce:sup><ce:italic>P</ce:italic><ce:hsp sp="0.25"/>≤<ce:hsp sp="0.25"/>0.001 compared to no Mg<ce:sup>2+</ce:sup>; <ce:sup loc="pre">##</ce:sup><ce:italic>P</ce:italic><ce:hsp sp="0.25"/>≤<ce:hsp sp="0.25"/>0.001 compared to the absence of RGDS). (B) Washed platelets were prepared as in (A) and left to adhere for 15, 30, and 60<ce:hsp sp="0.25"/>min (<ce:sup loc="pre">∗</ce:sup><ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.05 compared to 15<ce:hsp sp="0.25"/>min). Adhesion in the presence of 1<ce:hsp sp="0.25"/>mM Mg<ce:sup>2+</ce:sup> after 15<ce:hsp sp="0.25"/>min was regarded as 100%.</ce:simple-para></ce:caption><ce:link locator="gr1"/></ce:figure><ce:figure id="fig2"><ce:label>Fig. 2</ce:label><ce:caption><ce:simple-para>NO-mediated inhibition of adhesion to immobilised fibrinogen. (A) Washed platelets (1<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup>8</ce:sup><ce:hsp sp="0.25"/>platelets/ml) were preincubated for 10<ce:hsp sp="0.25"/>min with GSNO (0–100<ce:hsp sp="0.25"/>μM), and ODQ (20<ce:hsp sp="0.25"/>μM) as indicated, and allowed to adhere to fibrinogen-coated wells at 37<ce:hsp sp="0.25"/>°C for 15<ce:hsp sp="0.25"/>min (<ce:sup loc="pre">∗∗</ce:sup><ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.001 compared to no GSNO treatment). (B) Washed platelets (5<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup>8</ce:sup> platelets/ml) were preincubated with GSNO and added to fibrinogen-coated wells (6-well plates) in the presence and absence of ODQ (20<ce:hsp sp="0.25"/>μM) for up to 30<ce:hsp sp="0.25"/>min. Cells were lysed, separated by SDS–PAGE and immunoblotted for phosphoVASP-serine<ce:sup>239</ce:sup> and reprobed for β-tubulin. The blot is representative of three independent experiments. (C) and (D) Platelets were adhered to fibrinogen-coated coverslips for 15<ce:hsp sp="0.25"/>min at 37<ce:hsp sp="0.25"/>°C in absence (C) and presence (D) of GSNO (100<ce:hsp sp="0.25"/>μM). Adherent platelets were stained for F-actin with TRITC-conjugated phalloidin. The data are then expressed as means<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>S.E.M. of three number of adherent per 0.1<ce:hsp sp="0.25"/>mm<ce:sup>2</ce:sup> independent experiments performed in duplicate (<ce:sup loc="pre">∗</ce:sup><ce:italic>P</ce:italic><ce:hsp sp="0.25"/>≤<ce:hsp sp="0.25"/>0.05).</ce:simple-para></ce:caption><ce:link locator="gr2"/></ce:figure><ce:figure id="fig3"><ce:label>Fig. 3</ce:label><ce:caption><ce:simple-para>NO reduces adhesion induced tyrosine phosphorylation of platelet proteins. (A) Washed platelets (5<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup>8</ce:sup> platelets/ml) were adhered to fibrinogen-coated wells (6-well plates) in the presence and absence of GSNO (100<ce:hsp sp="0.25"/>μM) for up to 60<ce:hsp sp="0.25"/>min at 37<ce:hsp sp="0.25"/>°C. In control experiments platelets were also incubated in wells coated with heat-inactivated human serum (HS). At the appropriate times, cells were lysed, the lysate proteins were separated by SDS–PAGE (10–18%) and immunoblotted for phosphotyrosine. The blot shown is representative of three independent experiments. (B) Densitometry measurement of the 90<ce:hsp sp="0.25"/>kDa band expressed as ratio of pY/total Syk and presented as means<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>S.E.M. of three independent experiments (<ce:sup loc="pre">∗</ce:sup><ce:italic>P</ce:italic><ce:hsp sp="0.25"/>≤<ce:hsp sp="0.25"/>0.05).</ce:simple-para></ce:caption><ce:link locator="gr3"/></ce:figure><ce:figure id="fig4"><ce:label>Fig. 4</ce:label><ce:caption><ce:simple-para>Effect of NO on phosphorylation of cytoplasmic tyrosine residues in adherent platelets. (A) Washed platelets (3<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup>8</ce:sup> platelets/ml) were incubated with in the presence (lane 2) and absence (lane 1) fibrinogen (250<ce:hsp sp="0.25"/>μg/ml)/Mn<ce:sup>2+</ce:sup> (1<ce:hsp sp="0.25"/>mM) 37<ce:hsp sp="0.25"/>°C for 15<ce:hsp sp="0.25"/>min. (B) Washed platelets (5<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup>8</ce:sup> platelets/ml) were adhered to fibrinogen-coated wells (6-well plates) in the presence and absence of GSNO for 15<ce:hsp sp="0.25"/>min at 37<ce:hsp sp="0.25"/>°C. (C) Washed platelets (3<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup>8</ce:sup><ce:hsp sp="0.25"/>platelets/ml) were incubated with fibrinogen (250<ce:hsp sp="0.25"/>μg/ml) in the presence of 1<ce:hsp sp="0.25"/>mM Mn<ce:sup>2+</ce:sup> 37<ce:hsp sp="0.25"/>°C for 15<ce:hsp sp="0.25"/>min. Cells were lysed and processed as in (A). (D) Platelets were treated as in (C) except that in some cases the platelets were preincubated with ODQ (20<ce:hsp sp="0.25"/>μM). In all cases cells were lysed with Laemmli buffer and after normalisation of protein content, the lysate proteins were separated by SDS–PAGE (10–18%) immunoblotted for phosphotyrosine, phospho-β<ce:inf>3</ce:inf>Y<ce:sup>773</ce:sup>, and phospho-β<ce:inf>3</ce:inf>Y<ce:sup>785</ce:sup>. Membranes were subsequently stripped and reprobed with a total β<ce:inf>3</ce:inf> antibody. Densitometry analysis was conducted on integrin β<ce:inf>3</ce:inf>-pY<ce:sup>773</ce:sup>, integrin β<ce:inf>3</ce:inf>-pY<ce:sup>785</ce:sup>, and total integrin β<ce:inf>3</ce:inf>-pY. Results represent the means<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>S.E.M. of four independent experiments expressed as percentage change, calculated using the ratio of the according pY/total β<ce:inf>3</ce:inf>. Ratio obtained in the absence of NO treatment was considered 100% (<ce:sup loc="pre">∗</ce:sup><ce:italic>P</ce:italic><ce:hsp sp="0.25"/>≤<ce:hsp sp="0.25"/>0.05 and <ce:sup loc="pre">∗∗</ce:sup><ce:italic>P</ce:italic><ce:hsp sp="0.25"/>≤<ce:hsp sp="0.25"/>0.001 compared to no GSNO treatment).</ce:simple-para></ce:caption><ce:link locator="gr4"/></ce:figure></ce:floats><head><ce:title xmlns:ce="http://www.elsevier.com/xml/common/dtd">cGMP-independent inhibition of integrin α<ce:inf>IIb</ce:inf>β<ce:inf>3</ce:inf>-mediated platelet adhesion and outside-in signalling by nitric oxide</ce:title><ce:presented xmlns:ce="http://www.elsevier.com/xml/common/dtd">Edited by Lukas Huber</ce:presented><ce:author-group xmlns:ce="http://www.elsevier.com/xml/common/dtd"><ce:author><ce:given-name>Nikolaus G.</ce:given-name><ce:surname>Oberprieler</ce:surname><ce:cross-ref refid="aff1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Wayne</ce:given-name><ce:surname>Roberts</ce:surname><ce:cross-ref refid="aff1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Anne M.</ce:given-name><ce:surname>Graham</ce:surname><ce:cross-ref refid="aff1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Shervanthi</ce:given-name><ce:surname>Homer-Vanniasinkam</ce:surname><ce:cross-ref refid="aff1"><ce:sup>a</ce:sup></ce:cross-ref><ce:cross-ref refid="aff2"><ce:sup>b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Khalid M.</ce:given-name><ce:surname>Naseem</ce:surname><ce:cross-ref refid="aff1"><ce:sup>a</ce:sup></ce:cross-ref><ce:cross-ref refid="cor1"><ce:sup>⁎</ce:sup></ce:cross-ref><ce:e-address type="email">k.m.naseem@bradford.ac.uk</ce:e-address></ce:author><ce:affiliation id="aff1"><ce:label>a</ce:label><ce:textfn>Centre for Atherothrombosis Research, Department of Medical Biosciences, University of Bradford, Richmond Building, Richmond Road, Bradford, West Yorkshire BD7 1DP, UK</ce:textfn></ce:affiliation><ce:affiliation id="aff2"><ce:label>b</ce:label><ce:textfn>Vascular Surgical Unit, Leeds General Infirmary, Leeds, West Yorkshire LS1 3EX, UK</ce:textfn></ce:affiliation><ce:correspondence id="cor1"><ce:label>⁎</ce:label><ce:text>Corresponding author. Fax: +44 1274 309742.</ce:text></ce:correspondence></ce:author-group><ce:abstract class="author" xml:lang="en" xmlns:ce="http://www.elsevier.com/xml/common/dtd"><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>We examined the influence of <ce:italic>S</ce:italic>-nitrosoglutathione (GSNO) on α<ce:inf>IIb</ce:inf>β<ce:inf>3</ce:inf> integrin-mediated platelet adhesion to immobilised fibrinogen. GSNO induced a time- and concentration-dependent inhibition of platelet adhesion. Inhibition was cGMP-independent and associated with both reduced platelet spreading and protein tyrosine phosphorylation. To investigate the cGMP-independent effects of NO we evaluated integrin β<ce:inf>3</ce:inf> phosphorylation. Adhesion to fibrinogen induced rapid phosphorylation of β<ce:inf>3</ce:inf> on tyrosines 773 and 785, which was reduced by GSNO in a cGMP independent manner. Similar results were observed in suspended platelets indicating that NO-induced effects were independent of spreading-induced signalling. This is the first demonstration that NO directly regulates integrin β<ce:inf>3</ce:inf> phosphorylation.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords class="keyword" xmlns:ce="http://www.elsevier.com/xml/common/dtd"><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Nitric oxide</ce:text></ce:keyword><ce:keyword><ce:text>Platelets</ce:text></ce:keyword><ce:keyword><ce:text>cGMP</ce:text></ce:keyword><ce:keyword><ce:text>Integrin α<ce:inf>IIb</ce:inf>β<ce:inf>3</ce:inf></ce:text></ce:keyword><ce:keyword><ce:text>Tyrosine phosphorylation</ce:text></ce:keyword></ce:keywords></head><body><ce:sections xmlns:ce="http://www.elsevier.com/xml/common/dtd"><ce:section><ce:label>1</ce:label><ce:section-title>Introduction</ce:section-title><ce:para>The integrin α<ce:inf>IIb</ce:inf>β<ce:inf>3</ce:inf> mediates platelet adhesion to immobilised fibrinogen. α<ce:inf>IIb</ce:inf>β<ce:inf>3</ce:inf> is found on the platelet surface in a cryptic low affinity form, but upon inside-out signalling induced by platelet agonists, it is converted to its high affinity form capable of ligand binding. α<ce:inf>IIb</ce:inf>β<ce:inf>3</ce:inf> is targeted by intracellular signalling cascades, but can also initiate outside-in signalling. Signalling through α<ce:inf>IIb</ce:inf>β<ce:inf>3</ce:inf> results in activation of protein tyrosine phosphorylation signalling events and determines the extent of platelet spreading on von Willebrand Factor or fibrinogen surfaces and their resistance to detachment <ce:cross-refs refid="bib1 bib2">[1,2]</ce:cross-refs>. The cytoplasmic tail of the β-integrin is considered critical to integrin-mediated platelet spreading through interactions with the cytoskeleton <ce:cross-refs refid="bib3 bib4">[3,4]</ce:cross-refs>. Ligand-induced phosphorylation of β<ce:inf>3</ce:inf>-integrin leads to its interaction with signalling proteins such as the Src family kinases, Syk, protein kinase C, phospholipase Cγ2 and with structural cytoskeletal proteins such as α-actinin and talin <ce:cross-refs refid="bib2 bib3 bib4 bib5">[2–5]</ce:cross-refs>. Although a model for the activation of outside-in signalling pathways is emerging, little is known of the negative regulation of integrin signalling.</ce:para><ce:para>Nitric oxide (NO) acts to both inhibit platelet adhesion to the extra cellular matrix (ECM) and limit platelet aggregation <ce:cross-refs refid="bib6 bib7">[6,7]</ce:cross-refs>. NO blunts agonist-induced biochemical signalling in suspended platelets leading to reduced integrin activation, Ca<ce:sup>2+</ce:sup> mobilisation, secretion and thromboxane A<ce:inf>2</ce:inf> (TxA<ce:inf>2</ce:inf>) release <ce:cross-ref refid="bib8">[8]</ce:cross-ref>. While it is established that NO inhibits inside-out signalling and α<ce:inf>IIb</ce:inf>β<ce:inf>3</ce:inf> activation induced by agonists <ce:cross-ref refid="bib9">[9]</ce:cross-ref>, it is unclear if NO inhibits outside-in signalling mediated through β<ce:inf>3</ce:inf> phosphorylation. We examined the effects of NO on outside-in signalling using platelet adhesion and β<ce:inf>3</ce:inf> phosphorylation as markers of integrin function. Our data demonstrate that NO reduces integrin-mediated signalling in a cGMP-independent manner, via modulation of β<ce:inf>3</ce:inf> phosphorylation suggesting a novel mechanism of NO action in platelet signalling.</ce:para></ce:section><ce:section role="materials-methods"><ce:label>2</ce:label><ce:section-title>Materials and methods</ce:section-title><ce:section><ce:label>2.1</ce:label><ce:section-title>Materials</ce:section-title><ce:para>The antibodies used were anti-phosphotyrosine monoclonal antibody (MoAb) 4G10 (Upstate Biotechnology Inc., Milton Keynes, UK), anti-Syk mouse MoAb (Santa Cruz, Herts., UK), phospho-Ser 239 VASP and anti-integrin β<ce:inf>3</ce:inf> antibodies (Cell Signalling Technology, Hitchin, UK), phospho-Tyr 773 phospho-Tyr 785 integrin β<ce:inf>3</ce:inf> (Biosource Intern., CA, USA), anti-mouse and anti-rabbit IgG HRP (Amersham Biosciences, Bucks., UK). DC protein assay kit was purchased from Bio-Rad (Hemel-Hempstead, Herts., UK). 1H-[1,2,4]-Oxadiazolo [4, 3-a] hyquinoxalin-1-one (ODQ) was obtained from Calbiochem (Nottingham, UK). All other reagents were from Sigma Ltd (Poole, UK).</ce:para></ce:section><ce:section><ce:label>2.2</ce:label><ce:section-title>Platelet preparation</ce:section-title><ce:para>Human blood was taken from drug-free volunteers using acid citrate dextrose (29.9<ce:hsp sp="0.25"/>mM Na citrate, 113.8<ce:hsp sp="0.25"/>mM glucose, 72.6<ce:hsp sp="0.25"/>mM NaCl and 2.9<ce:hsp sp="0.25"/>mM citric acid, pH 6.4) as anticoagulant. Washed platelets were prepared by the prostaglandin method <ce:cross-ref refid="bib10">[10]</ce:cross-ref> and were incubated with ayprase and indomethacin (10<ce:hsp sp="0.25"/>μM) to abrogate the effects of ADP, and T<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>A<ce:inf>2</ce:inf> respectively.</ce:para></ce:section><ce:section><ce:label>2.3</ce:label><ce:section-title>Platelet adhesion assay</ce:section-title><ce:para>96-well micro titre plates were coated using fibrinogen (1<ce:hsp sp="0.25"/>mg/ml) or heat-inactivated human serum (HS) for 24<ce:hsp sp="0.25"/>h at 4<ce:hsp sp="0.25"/>°C and blocked with HS (5%) diluted in PBS. Platelets were incubated with inhibitors for the required time and then allowed to adhere at 37<ce:hsp sp="0.25"/>°C for the indicated time. Non-adherent platelets were removed and adherent platelets were incubated with 0.1<ce:hsp sp="0.25"/>M citrate buffer containing 5 mM <ce:italic>p</ce:italic>-nitrophenol phosphate and 0.1% Triton X-100 (31<ce:hsp sp="0.25"/>mM citric acid, 5<ce:hsp sp="0.25"/>mM sodium citrate dehydrate, 5<ce:hsp sp="0.25"/>mM <ce:italic>p</ce:italic>-nitrophenyl phosphate, 0.1% (v/v) Triton X-100, pH 5.4) for 1<ce:hsp sp="0.25"/>h at room temperature. The reaction product was visualised using 2<ce:hsp sp="0.25"/>N NaOH at 405<ce:hsp sp="0.25"/>nm <ce:cross-ref refid="bib11">[11]</ce:cross-ref>. None of the platelet reagents used had any effect on platelet acid phosphatase activity (not shown).</ce:para></ce:section><ce:section><ce:label>2.4</ce:label><ce:section-title>Microscopy</ce:section-title><ce:para>Platelets (2<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup>7</ce:sup>/ml) were adhered to fibrinogen (1<ce:hsp sp="0.25"/>mg/ml)-coated coverslips for 30<ce:hsp sp="0.25"/>min at 37<ce:hsp sp="0.25"/>°C. In the presence and absence of GSNO (100<ce:hsp sp="0.25"/>μM). Non-adherent platelets were removed, and adherent platelets were fixed with 4% paraformaldehyde and permeablised with 0.1% Triton-X-100. Platelets were stained for F-actin using tetramethylrhodamine isothiocyanate (TRITC)-conjugated phalloidin and visualised using Fluorescent microscope (Nikon Eclipse 80i). For each experiment, the number of platelets from eight random fields of view were added and the results calculated as mean number of adherent platelet<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>S.E.M. per 0.1<ce:hsp sp="0.25"/>mm<ce:sup>2</ce:sup>.</ce:para></ce:section><ce:section><ce:label>2.5</ce:label><ce:section-title>Immunoblotting studies</ce:section-title><ce:para>Platelets (5<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup>8</ce:sup>/ml) were adhered to fibrinogen (1<ce:hsp sp="0.25"/>mg/ml)-coated wells (six-well plates) in the presence or absence of GSNO for up to 60<ce:hsp sp="0.25"/>min. Non-adherent platelets were removed and adherent platelets lysed by the addition of Laemmli sample buffer (1×). For VASP studies both adherent and non-adherent platelets were immunoblotted. After accounting for fibrinogen, lysate protein (20<ce:hsp sp="0.25"/>μg) was subjected to SDS–PAGE (10–18%) and then transferred to polyvinylidene difluoride (PVDF) membranes. Membranes were probed with either anti-phosphotyrosine 4G10 (1:1000), anti-phospho-β<ce:inf>3</ce:inf>Y<ce:sup>773</ce:sup>, anti-phospho-β<ce:inf>3</ce:inf>Y<ce:sup>785</ce:sup> (1:1000) or anti phosphoserine<ce:sup>239</ce:sup> VASP (1:1000), and stripped and reprobed with either anti-Syk (1:2000), anti-β<ce:inf>3</ce:inf> or anti-VASP. All antibodies were diluted in TBS-T containing 2% BSA Membranes were visualised with enhanced chemiluminescence (ECL). Densitometric analyses were performed using Scion Image program (NIH), and expressed as a ratio of phosphotyrosine to total Syk or total β<ce:inf>3</ce:inf>. Protein concentrations were determined in platelet lysates using the BioRad protein assay using bovine serum albumin as standard.</ce:para></ce:section><ce:section><ce:label>2.6</ce:label><ce:section-title>Statistical analysis</ce:section-title><ce:para>Results are expressed as means<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>S.E.M. and were analysed using the Student’s <ce:italic>t</ce:italic>-test or ANOVA for unpaired data as appropriate. The results were considered significant when <ce:italic>P</ce:italic> values were &lt;0.05.</ce:para></ce:section></ce:section><ce:section><ce:label>3</ce:label><ce:section-title>Results</ce:section-title><ce:section><ce:label>3.1</ce:label><ce:section-title>The effect of exogenous NO on integrin α<ce:inf>IIb</ce:inf>β<ce:inf>3</ce:inf>-mediated platelet adhesion</ce:section-title><ce:para>Incubation of platelets in fibrinogen coated wells in the absence of platelets agonists led to a significant increase in platelet adhesion. This response was α<ce:inf>IIb</ce:inf>β<ce:inf>3</ce:inf>-dependent since preincubation of platelets with Arg-Gly-Asp-Ser peptide (RDGS; 2<ce:hsp sp="0.25"/>mM), an α<ce:inf>IIb</ce:inf>β<ce:inf>3</ce:inf> peptide blocker, ablated adhesion (<ce:italic>P</ce:italic><ce:hsp sp="0.25"/>&lt;<ce:hsp sp="0.25"/>0.001; <ce:cross-ref refid="fig1">Fig. 1</ce:cross-ref><ce:float-anchor refid="fig1"/>). Incubation with GSNO led to a concentration-dependent inhibition of platelet adhesion to immobilised fibrinogen (ANOVA: <ce:italic>P</ce:italic><ce:hsp sp="0.25"/>≤<ce:hsp sp="0.25"/>0.001) (<ce:cross-ref refid="fig2">Fig. 2</ce:cross-ref><ce:float-anchor refid="fig2"/>A). After 15<ce:hsp sp="0.25"/>min, adhesion was inhibited by 16.5<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>8.4% (<ce:italic>P</ce:italic><ce:hsp sp="0.25"/>≤<ce:hsp sp="0.25"/>0.05) using 1<ce:hsp sp="0.25"/>μM GSNO, and maximal effects observed at 100<ce:hsp sp="0.25"/>μM GSNO (41.5<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>4.6%, <ce:italic>P</ce:italic><ce:hsp sp="0.25"/>≤<ce:hsp sp="0.25"/>0.001) (<ce:cross-ref refid="fig2">Fig. 2</ce:cross-ref>A, black fill). Similar results were obtained with a structurally distinct NO donor, DPTA-NONOate, while NO-depleted GSNO had no effect (not shown).</ce:para><ce:para>GSNO inhibits platelet aggregation through cGMP-dependent and independent mechanisms <ce:cross-refs refid="bib12 bib13">[12,13]</ce:cross-refs>, however it is unknown if the same is true for integrin-driven adhesion. To address this issue we used the soluble guanylyl cyclase (sGC) inhibitor ODQ <ce:cross-ref refid="bib14">[14]</ce:cross-ref>. GSNO (100<ce:hsp sp="0.25"/>μM) inhibited platelet adhesion by 41.5<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>4.6%, which surprisingly was unaffected by the presence ODQ (20<ce:hsp sp="0.25"/>μM) (43.8<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>5.2% <ce:cross-ref refid="fig2">Fig. 2</ce:cross-ref>A), suggesting that integrin α<ce:inf>Iib</ce:inf>β<ce:inf>3</ce:inf>-mediated outside-in signalling and adhesion is inhibited by GSNO in a sGC-independent manner. ODQ ablated NO-induced sGC activity as evidenced by the inhibition of VASP phosphorylation at serine<ce:sup>239</ce:sup>, as a marker of the NO/sGC/Protein kinase G (PKG) signalling pathway <ce:cross-ref refid="bib15">[15]</ce:cross-ref>. Furthermore, ODQ completely inhibited GSNO-induced cGMP formation in suspended platelets (not shown). Thus, NO-mediated inhibition of adhesion under these conditions occurs via a cGMP-independent mechanism. The platelet adhesion assay results were confirmed by staining of the actin cytoskeleton using TRITC-labelled phalloidin. Platelets adhered to fibrinogen and underwent the full range of morphological changes from filopodia formation to full spreading (<ce:cross-ref refid="fig2">Fig. 2</ce:cross-ref>C and D). The number of platelets forming stable adhesions on fibrinogen was 182<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>12 per 0.1<ce:hsp sp="0.25"/>mm<ce:sup>2</ce:sup>, which was reduced to 114.0<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>1 platelets/0.1<ce:hsp sp="0.25"/>mm<ce:sup>2</ce:sup> in the presence of GSNO(10<ce:hsp sp="0.25"/>μM) (<ce:cross-ref refid="fig2">Fig. 2</ce:cross-ref>C and D), representing a 36% reduction in platelet adhesion (<ce:italic>P</ce:italic><ce:hsp sp="0.25"/>≤<ce:hsp sp="0.25"/>0.01). Furthermore, GSNO was able to inhibit the ability of adherent platelets to spread (<ce:cross-ref refid="fig2">Fig. 2</ce:cross-ref>D).</ce:para></ce:section><ce:section><ce:label>3.2</ce:label><ce:section-title>Effect of NO on integrin α<ce:inf><ce:italic>IIb</ce:italic></ce:inf>β<ce:inf>3</ce:inf>-mediated outside-in signalling</ce:section-title><ce:para>β<ce:inf>3</ce:inf> phosphorylation is critical to facilitating the platelet adhesion response through initiation of signalling cascades that lead to actin polymerisation <ce:cross-refs refid="bib16 bib17">[16,17]</ce:cross-refs>. Integrin α<ce:inf>IIb</ce:inf>β<ce:inf>3</ce:inf>-mediated adhesion to immobilised fibrinogen for 15<ce:hsp sp="0.25"/>min induced tyrosine phosphorylation in a number of proteins, with robust phosphorylation observed in proteins apparent molecular weights of approximately 125<ce:hsp sp="0.25"/>kDa, 90<ce:hsp sp="0.25"/>kDa, 72<ce:hsp sp="0.25"/>kDa 55<ce:hsp sp="0.25"/>kDa and 39<ce:hsp sp="0.25"/>kDa (<ce:cross-ref refid="fig3">Fig. 3</ce:cross-ref><ce:float-anchor refid="fig3"/>A). Beyond this time point adhesion induced tyrosine phosphorylation decreased (<ce:cross-ref refid="fig3">Fig. 3</ce:cross-ref>B). In the presence of GSNO tyrosine phosphorylation of a number of proteins was inhibited, with the most notable reduction was observed at 15mins with the 90<ce:hsp sp="0.25"/>kDa protein band (<ce:italic>P</ce:italic><ce:hsp sp="0.25"/>≤<ce:hsp sp="0.25"/>0.05; <ce:cross-ref refid="fig3">Fig. 3</ce:cross-ref>B).</ce:para></ce:section><ce:section><ce:label>3.3</ce:label><ce:section-title>Effect of NO on individual integrinβ<ce:inf>3</ce:inf>phosphorylation sites</ce:section-title><ce:para>The integrin β<ce:inf>3</ce:inf> becomes phosphorylated on tyrosine<ce:sup>773</ce:sup> and tyrosine<ce:sup>785</ce:sup> (human sequence) in response to ligand binding <ce:cross-ref refid="bib18">[18]</ce:cross-ref> (<ce:cross-ref refid="fig4">Fig. 4</ce:cross-ref><ce:float-anchor refid="fig4"/>A). Since the 90<ce:hsp sp="0.25"/>kDa phosphoprotein could represent integrin β<ce:inf>3</ce:inf> (<ce:cross-ref refid="fig4">Fig. 4</ce:cross-ref>A), we investigated whether both residues become phosphorylated during platelet adhesion and whether NO exhibits its inhibitory effect in a tyrosine residue specific manner. Immunoblotting of proteins from adherent platelets or suspended platelets treated with fibrinogen demonstrated increased phosphorylation of tyrosine<ce:sup>773/783</ce:sup> (<ce:cross-ref refid="fig4">Fig. 4</ce:cross-ref>B), which was inhibited significantly by GSNO (100<ce:hsp sp="0.25"/>μM) (<ce:italic>P</ce:italic><ce:hsp sp="0.25"/>≤<ce:hsp sp="0.25"/>0.05). Since NO inhibits platelet adhesion and spreading, the reduced tyrosine phosphorylation of β<ce:inf>3</ce:inf> may represent a reduced spreading induced signalling. To obviate spreading induced signalling the experiments were repeated in suspended platelets using soluble fibrinogen (250<ce:hsp sp="0.25"/>μg/ml) in the presence of 1<ce:hsp sp="0.25"/>mM Mn<ce:sup>2+</ce:sup> <ce:cross-ref refid="bib16">[16]</ce:cross-ref>. Under these conditions β<ce:inf>3</ce:inf> phosphorylation at tyrosine<ce:sup>773/783</ce:sup> was increased and consistent with adhesion experiments was inhibited significantly by GSNO (100<ce:hsp sp="0.25"/>μM) (<ce:cross-ref refid="fig4">Fig. 4</ce:cross-ref>C). When platelets were exposed to NO (100<ce:hsp sp="0.25"/>μM GSNO) in the presence and absence of ODQ, tyrosine phosphorylation of the integrin remained inhibited (<ce:cross-ref refid="fig4">Fig. 4</ce:cross-ref>D, lanes 1 and 4).</ce:para></ce:section></ce:section><ce:section><ce:label>4</ce:label><ce:section-title>Discussion</ce:section-title><ce:para>Platelet adhesion and spreading on immobilised fibrinogen occurs in the absence of exogenously added platelet agonists <ce:cross-ref refid="bib19">[19]</ce:cross-ref>. We used this phenomenon to study the effects NO on integrin signalling. NO induced a sustained inhibition of adhesion, which was concentration dependent, but also reduced platelet spreading on fibrinogen. Platelet spreading is required for stable adhesion and it is possible that NO blocks spreading leading to reduced adhesion. Interestingly complete inhibition of adhesion was never attained regardless of time of incubation or concentration of NO used. Thus, a significant proportion of the adhesion response to immobilised fibrinogen is resistant to NO even at high concentrations. The reasons for this are unclear since GSNO at these concentrations completely inhibits agonist-induced aggregation and fibrinogen binding <ce:cross-refs refid="bib9 bib20">[9,20]</ce:cross-refs>. These high concentrations of NO are associated with cGMP independent effects on platelets. Certainly the kinetics of the adhesion assay would suggest that cGMP levels, which peak approximately 1<ce:hsp sp="0.25"/>min after exposure to NO <ce:cross-ref refid="bib21">[21]</ce:cross-ref>, would have return to basal before significant adhesion had taken place favouring a cGMP independent mechanism. Indeed, NO-mediated platelet adhesion was cGMP-independent despite activation of the PKG signalling pathway. It is possible that cGMP signalling is important for short term regulation of platelets, but prolonged inhibition is mediated by cGMP-independent mechanisms. Furthermore adhesion-induced (outside-in) signalling generated by adherent platelets under static conditions is more resistant to the actions of NO, whether they are cGMP-dependent or independent, compared to stimulation of platelets in suspension.</ce:para><ce:para>Platelet adhesion and spreading on fibrinogen activates protein tyrosine phosphorylation signalling cascades <ce:cross-refs refid="bib5 bib22">[5,22]</ce:cross-refs>. We observed robust phosphorylation of proteins of apparent molecular weights of 125<ce:hsp sp="0.25"/>kDa, 90<ce:hsp sp="0.25"/>kDa, 72<ce:hsp sp="0.25"/>kDa, 55<ce:hsp sp="0.25"/>kDa and 39<ce:hsp sp="0.25"/>kDa. Interestingly NO specifically reduced phosphorylation of the 90<ce:hsp sp="0.25"/>kDa protein band. Since β<ce:inf>3</ce:inf>integrin has an apparent molecular weight of 90<ce:hsp sp="0.25"/>kDa, we tested the effects of NO on β<ce:inf>3</ce:inf> phosphorylation. Platelet adhesion was associated with β<ce:inf>3</ce:inf> phosphorylation on two residues, tyrosine 773 and 785. Importantly the level of phosphorylation was reduced by the presence of GSNO. Importantly, GSNO also inhibited tyrosine phosphorylation of β<ce:inf>3</ce:inf> induced by soluble fibrinogen in the presence of Mn<ce:sup>2+</ce:sup>, indicating that NO inhibited phosphorylation directly by reducing spreading-induced signalling. Thus, NO inhibits β<ce:inf>3</ce:inf> phosphorylation, which is associated with a reduced adhesion and spreading response.</ce:para><ce:para>The precise cGMP-independent mechanism by which NO regulates integrin function remains elusive. Possible mechanisms of action for NO, independent of soluble guanylyl cyclase include protein <ce:italic>S</ce:italic>-nitrosylation and nitration. The integrin α<ce:inf>IIb</ce:inf>β<ce:inf>3</ce:inf> has an extracellular cysteine-rich domain in the β<ce:inf>3</ce:inf> subunit that includes a number of unpaired cysteines. Rearrangement of disulfide bonds in an enzyme dependent process is required in order to allow fibrinogen binding to the integrin <ce:cross-refs refid="bib23 bib24 bib25">[23–25]</ce:cross-refs>. NO can induce <ce:italic>S</ce:italic>-nitrosylation of cysteine residues in a number of proteins leading to altered function. <ce:italic>S</ce:italic>-nitrosylation of β<ce:inf>3</ce:inf> by NO would prevent sulfhydryl rearrangement within the integrin and render the integrin either unable to engage with fibrinogen effectively or affect its ability to transduce signals. An alternative mechanism may involve protein disulphide isomerase (PDI), an enzyme that rearranges disulphide bonds, which is present on the platelet surface and has been implicated in facilitating integrin activation <ce:cross-ref refid="bib23">[23]</ce:cross-ref>. A recent study by Uehara et al. demonstrated the inhibition of PDI by <ce:italic>S</ce:italic>-nitrosylation in cerebrocortical neurons <ce:cross-ref refid="bib26">[26]</ce:cross-ref>. If NO inhibits platelet PDI this could result in failure to facilitate integrin activation. Certainly a mechanism involving <ce:italic>S</ce:italic>-nitrosylation is consistent with the higher concentrations of NO required in inhibit integrin function, since sGC activation occurs at much lower concentrations <ce:cross-ref refid="bib27">[27]</ce:cross-ref>. In conclusion our data demonstrate for the first time that NO inhibits β<ce:inf>3</ce:inf> phosphorylation, integrin-mediated outside-in signalling leading to reduced platelet adhesion, in a cGMP-independent manner.</ce:para></ce:section></ce:sections><ce:acknowledgment xmlns:ce="http://www.elsevier.com/xml/common/dtd"><ce:section-title>Acknowledgments</ce:section-title><ce:para>This work was funded by the University of Bradford, Leeds Surgical Research Fund and Heart Research, UK.</ce:para></ce:acknowledgment></body><tail><ce:bibliography xmlns:ce="http://www.elsevier.com/xml/common/dtd"><ce:section-title>References</ce:section-title><ce:bibliography-sec><ce:bib-reference id="bib1"><ce:label>[1]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Gao</ce:surname></sb:author><sb:author><ce:given-name>K.E.</ce:given-name><ce:surname>Zoller</ce:surname></sb:author><sb:author><ce:given-name>M.H.</ce:given-name><ce:surname>Ginsberg</ce:surname></sb:author><sb:author><ce:given-name>J.S.</ce:given-name><ce:surname>Brugge</ce:surname></sb:author><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Shattil</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Regulation of the pp72syk protein tyrosine kinase by platelet integrin alpha IIb beta 3</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>EMBO J.</sb:maintitle></sb:title><sb:volume-nr>16</sb:volume-nr></sb:series><sb:date>1997</sb:date></sb:issue><sb:pages><sb:first-page>6414</sb:first-page><sb:last-page>6425</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib2"><ce:label>[2]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>D.A.</ce:given-name><ce:surname>Calderwood</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Zent</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Grant</ce:surname></sb:author><sb:author><ce:given-name>D.J.</ce:given-name><ce:surname>Rees</ce:surname></sb:author><sb:author><ce:given-name>R.O.</ce:given-name><ce:surname>Hynes</ce:surname></sb:author><sb:author><ce:given-name>M.H.</ce:given-name><ce:surname>Ginsberg</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The Talin head domain binds to integrin beta subunit cytoplasmic tails and regulates integrin activation</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biol. Chem.</sb:maintitle></sb:title><sb:volume-nr>274</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>28071</sb:first-page><sb:last-page>28074</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib3"><ce:label>[3]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>D.A.</ce:given-name><ce:surname>Calderwood</ce:surname></sb:author><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Shattil</ce:surname></sb:author><sb:author><ce:given-name>M.H.</ce:given-name><ce:surname>Ginsberg</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Integrins and actin filaments: reciprocal regulation of cell adhesion and signaling</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biol. Chem.</sb:maintitle></sb:title><sb:volume-nr>275</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>22607</sb:first-page><sb:last-page>22610</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib4"><ce:label>[4]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Shattil</ce:surname></sb:author><sb:author><ce:given-name>P.J.</ce:given-name><ce:surname>Newman</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Integrins: dynamic scaffolds for adhesion and signaling in platelets</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Blood</sb:maintitle></sb:title><sb:volume-nr>104</sb:volume-nr></sb:series><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>1606</sb:first-page><sb:last-page>1615</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib5"><ce:label>[5]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Wonerow</ce:surname></sb:author><sb:author><ce:given-name>A.C.</ce:given-name><ce:surname>Pearce</ce:surname></sb:author><sb:author><ce:given-name>D.J.</ce:given-name><ce:surname>Vaux</ce:surname></sb:author><sb:author><ce:given-name>S.P.</ce:given-name><ce:surname>Watson</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>A critical role for phospholipase Cgamma2 in alphaIIbbeta3-mediated platelet spreading</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biol. Chem.</sb:maintitle></sb:title><sb:volume-nr>278</sb:volume-nr></sb:series><sb:date>2003</sb:date></sb:issue><sb:pages><sb:first-page>37520</sb:first-page><sb:last-page>37529</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib6"><ce:label>[6]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Furlong</ce:surname></sb:author><sb:author><ce:given-name>A.H.</ce:given-name><ce:surname>Henderson</ce:surname></sb:author><sb:author><ce:given-name>M.J.</ce:given-name><ce:surname>Lewis</ce:surname></sb:author><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>Smith</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Endothelium-derived relaxing factor inhibits in vitro platelet aggregation</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Br. J. Pharmacol.</sb:maintitle></sb:title><sb:volume-nr>90</sb:volume-nr></sb:series><sb:date>1987</sb:date></sb:issue><sb:pages><sb:first-page>687</sb:first-page><sb:last-page>692</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib7"><ce:label>[7]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>J.C.</ce:given-name><ce:surname>de Graaf</ce:surname></sb:author><sb:author><ce:given-name>J.D.</ce:given-name><ce:surname>Banga</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Moncada</ce:surname></sb:author><sb:author><ce:given-name>R.M.</ce:given-name><ce:surname>Palmer</ce:surname></sb:author><sb:author><ce:given-name>P.G.</ce:given-name><ce:surname>de Groot</ce:surname></sb:author><sb:author><ce:given-name>J.J.</ce:given-name><ce:surname>Sixma</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Circulation</sb:maintitle></sb:title><sb:volume-nr>85</sb:volume-nr></sb:series><sb:date>1992</sb:date></sb:issue><sb:pages><sb:first-page>2284</sb:first-page><sb:last-page>2290</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib8"><ce:label>[8]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>B.L.</ce:given-name><ce:surname>Nguyen</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Saitoh</ce:surname></sb:author><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>Ware</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Interaction of nitric oxide and cGMP with signal transduction in activated platelets</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am. J. Physiol.</sb:maintitle></sb:title><sb:volume-nr>261</sb:volume-nr></sb:series><sb:date>1991</sb:date></sb:issue><sb:pages><sb:first-page>H1043</sb:first-page><sb:last-page>H1052</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib9"><ce:label>[9]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Keh</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Thieme</ce:surname></sb:author><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Kurer</ce:surname></sb:author><sb:author><ce:given-name>K.J.</ce:given-name><ce:surname>Falke</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Gerlach</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Inactivation of platelet glycoprotein IIb/IIIa receptor by nitric oxide donor 3-morpholino-sydnonimine</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Blood Coagul. Fibrinolysis</sb:maintitle></sb:title><sb:volume-nr>14</sb:volume-nr></sb:series><sb:date>2003</sb:date></sb:issue><sb:pages><sb:first-page>327</sb:first-page><sb:last-page>334</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib10"><ce:label>[10]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>J.R.</ce:given-name><ce:surname>Vargas</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Radomski</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Moncada</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The use of prostacyclin in the separation from plasma and washing of human platelets</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Prostaglandins</sb:maintitle></sb:title><sb:volume-nr>23</sb:volume-nr></sb:series><sb:date>1982</sb:date></sb:issue><sb:pages><sb:first-page>929</sb:first-page><sb:last-page>945</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib11"><ce:label>[11]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Bellavite</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Andrioli</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Guzzo</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Arigliano</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Chirumbolo</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Manzato</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Santonastaso</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>A colorimetric method for the measurement of platelet adhesion in microtiter plates</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Anal. Biochem.</sb:maintitle></sb:title><sb:volume-nr>216</sb:volume-nr></sb:series><sb:date>1994</sb:date></sb:issue><sb:pages><sb:first-page>444</sb:first-page><sb:last-page>450</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib12"><ce:label>[12]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Tsikas</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Ikic</ce:surname></sb:author><sb:author><ce:given-name>K.S.</ce:given-name><ce:surname>Tewes</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Raida</ce:surname></sb:author><sb:author><ce:given-name>J.C.</ce:given-name><ce:surname>Frolich</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Inhibition of platelet aggregation by S-nitroso-cysteine via cGMP-independent mechanisms: evidence of inhibition of thromboxane A2 synthesis in human blood platelets</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>FEBS Lett.</sb:maintitle></sb:title><sb:volume-nr>442</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>162</sb:first-page><sb:last-page>166</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib13"><ce:label>[13]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>M.S.</ce:given-name><ce:surname>Crane</ce:surname></sb:author><sb:author><ce:given-name>A.G.</ce:given-name><ce:surname>Rossi</ce:surname></sb:author><sb:author><ce:given-name>I.L.</ce:given-name><ce:surname>Megson</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>A potential role for extracellular nitric oxide generation in cGMP-independent inhibition of human platelet aggregation: biochemical and pharmacological considerations</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Br. J. Pharmacol.</sb:maintitle></sb:title><sb:volume-nr>144</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>849</sb:first-page><sb:last-page>859</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib14"><ce:label>[14]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>M.A.</ce:given-name><ce:surname>Moro</ce:surname></sb:author><sb:author><ce:given-name>R.J.</ce:given-name><ce:surname>Russel</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Cellek</ce:surname></sb:author><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Lizasoain</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Su</ce:surname></sb:author><sb:author><ce:given-name>V.M.</ce:given-name><ce:surname>Darley-Usmar</ce:surname></sb:author><sb:author><ce:given-name>M.W.</ce:given-name><ce:surname>Radomski</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Moncada</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Proc. Natl. Acad. Sci. USA</sb:maintitle></sb:title><sb:volume-nr>93</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>1480</sb:first-page><sb:last-page>1485</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib15"><ce:label>[15]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Halbrugge</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Friedrich</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Eigenthaler</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Schanzenbacher</ce:surname></sb:author><sb:author><ce:given-name>U.</ce:given-name><ce:surname>Walter</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Stoichiometric and reversible phosphorylation of a 46-kDa protein in human platelets in response to cGMP- and cAMP-elevating vasodilators</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biol. Chem.</sb:maintitle></sb:title><sb:volume-nr>265</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>3088</sb:first-page><sb:last-page>3093</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib16"><ce:label>[16]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Obergfell</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Eto</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Mocsai</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Buensuceso</ce:surname></sb:author><sb:author><ce:given-name>S.L.</ce:given-name><ce:surname>Moores</ce:surname></sb:author><sb:author><ce:given-name>J.S.</ce:given-name><ce:surname>Brugge</ce:surname></sb:author><sb:author><ce:given-name>C.A.</ce:given-name><ce:surname>Lowell</ce:surname></sb:author><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Shattil</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Cell Biol.</sb:maintitle></sb:title><sb:volume-nr>157</sb:volume-nr></sb:series><sb:date>2002</sb:date></sb:issue><sb:pages><sb:first-page>265</sb:first-page><sb:last-page>275</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib17"><ce:label>[17]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>D.G.</ce:given-name><ce:surname>Woodside</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Obergfell</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Leng</ce:surname></sb:author><sb:author><ce:given-name>J.L.</ce:given-name><ce:surname>Wilsbacher</ce:surname></sb:author><sb:author><ce:given-name>C.K.</ce:given-name><ce:surname>Miranti</ce:surname></sb:author><sb:author><ce:given-name>J.S.</ce:given-name><ce:surname>Brugge</ce:surname></sb:author><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Shattil</ce:surname></sb:author><sb:author><ce:given-name>M.H.</ce:given-name><ce:surname>Ginsberg</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Activation of Syk protein tyrosine kinase through interaction with integrin beta cytoplasmic domains</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Curr. Biol.</sb:maintitle></sb:title><sb:volume-nr>11</sb:volume-nr></sb:series><sb:date>2001</sb:date></sb:issue><sb:pages><sb:first-page>1799</sb:first-page><sb:last-page>1804</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib18"><ce:label>[18]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Kasirer-Friede</ce:surname></sb:author><sb:author><ce:given-name>M.R.</ce:given-name><ce:surname>Cozzi</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Mazzucato</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>De Marco</ce:surname></sb:author><sb:author><ce:given-name>Z.M.</ce:given-name><ce:surname>Ruggeri</ce:surname></sb:author><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Shattil</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Signaling through GP Ib-IX-V activates alpha IIb beta 3 independently of other receptors</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Blood</sb:maintitle></sb:title><sb:volume-nr>103</sb:volume-nr></sb:series><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>3403</sb:first-page><sb:last-page>3411</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib19"><ce:label>[19]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Shahbazi</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Jones</ce:surname></sb:author><sb:author><ce:given-name>M.W.</ce:given-name><ce:surname>Radomski</ce:surname></sb:author><sb:author><ce:given-name>M.A.</ce:given-name><ce:surname>Moro</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Gingell</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Nitric oxide donors inhibit platelet spreading on surfaces coated with fibrinogen but not with fibronectin</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Thromb. Res.</sb:maintitle></sb:title><sb:volume-nr>75</sb:volume-nr></sb:series><sb:date>1994</sb:date></sb:issue><sb:pages><sb:first-page>631</sb:first-page><sb:last-page>642</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib20"><ce:label>[20]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>A.D.</ce:given-name><ce:surname>Michelson</ce:surname></sb:author><sb:author><ce:given-name>S.E.</ce:given-name><ce:surname>Benoit</ce:surname></sb:author><sb:author><ce:given-name>M.I.</ce:given-name><ce:surname>Furman</ce:surname></sb:author><sb:author><ce:given-name>W.L.</ce:given-name><ce:surname>Breckwoldt</ce:surname></sb:author><sb:author><ce:given-name>M.J.</ce:given-name><ce:surname>Rohrer</ce:surname></sb:author><sb:author><ce:given-name>M.R.</ce:given-name><ce:surname>Barnard</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Loscalzo</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Effects of nitric oxide/EDRF on platelet surface glycoproteins</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Am. J. Physiol.</sb:maintitle></sb:title><sb:volume-nr>270</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>H1640</sb:first-page><sb:last-page>H1648</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib21"><ce:label>[21]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Mullershausen</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Friebe</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Feil</ce:surname></sb:author><sb:author><ce:given-name>W.J.</ce:given-name><ce:surname>Thompson</ce:surname></sb:author><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Hofmann</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Koesling</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Cell Biol.</sb:maintitle></sb:title><sb:volume-nr>160</sb:volume-nr></sb:series><sb:date>2003</sb:date></sb:issue><sb:pages><sb:first-page>719</sb:first-page><sb:last-page>727</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib22"><ce:label>[22]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Haimovich</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Lipfert</ce:surname></sb:author><sb:author><ce:given-name>J.S.</ce:given-name><ce:surname>Brugge</ce:surname></sb:author><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Shattil</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Tyrosine phosphorylation and cytoskeletal reorganization in platelets are triggered by interaction of integrin receptors with their immobilized ligands</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biol. Chem.</sb:maintitle></sb:title><sb:volume-nr>268</sb:volume-nr></sb:series><sb:date>1993</sb:date></sb:issue><sb:pages><sb:first-page>15868</sb:first-page><sb:last-page>15877</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib23"><ce:label>[23]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Lahav</ce:surname></sb:author><sb:author><ce:given-name>E.M.</ce:given-name><ce:surname>Wijnen</ce:surname></sb:author><sb:author><ce:given-name>O.</ce:given-name><ce:surname>Hess</ce:surname></sb:author><sb:author><ce:given-name>S.W.</ce:given-name><ce:surname>Hamaia</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Griffiths</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Makris</ce:surname></sb:author><sb:author><ce:given-name>C.G.</ce:given-name><ce:surname>Knight</ce:surname></sb:author><sb:author><ce:given-name>D.W.</ce:given-name><ce:surname>Essex</ce:surname></sb:author><sb:author><ce:given-name>R.W.</ce:given-name><ce:surname>Farndale</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Enzymatically catalyzed disulfide exchange is required for platelet adhesion to collagen via integrin alpha2beta1</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Blood</sb:maintitle></sb:title><sb:volume-nr>102</sb:volume-nr></sb:series><sb:date>2003</sb:date></sb:issue><sb:pages><sb:first-page>2085</sb:first-page><sb:last-page>2092</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib24"><ce:label>[24]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>D.W.</ce:given-name><ce:surname>Essex</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The role of thiols and disulfides in platelet function</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Antioxid. Redox Signal.</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>2004</sb:date></sb:issue><sb:pages><sb:first-page>736</sb:first-page><sb:last-page>746</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib25"><ce:label>[25]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>B.</ce:given-name><ce:surname>Yan</ce:surname></sb:author><sb:author><ce:given-name>J.W.</ce:given-name><ce:surname>Smith</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>A redox site involved in integrin activation</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Biol. Chem.</sb:maintitle></sb:title><sb:volume-nr>275</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>39964</sb:first-page><sb:last-page>39972</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib26"><ce:label>[26]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Uehara</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Nakamura</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Yao</ce:surname></sb:author><sb:author><ce:given-name>Z.Q.</ce:given-name><ce:surname>Shi</ce:surname></sb:author><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Gu</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Ma</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Masliah</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Nomura</ce:surname></sb:author><sb:author><ce:given-name>S.A.</ce:given-name><ce:surname>Lipton</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature</sb:maintitle></sb:title><sb:volume-nr>441</sb:volume-nr></sb:series><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>513</sb:first-page><sb:last-page>517</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib27"><ce:label>[27]</ce:label><sb:reference xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd"><sb:contribution><sb:authors><sb:author><ce:given-name>J.S.</ce:given-name><ce:surname>Stamler</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Lamas</ce:surname></sb:author><sb:author><ce:given-name>F.C.</ce:given-name><ce:surname>Fang</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Nitrosylation. the prototypic redox-based signaling mechanism</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell</sb:maintitle></sb:title><sb:volume-nr>106</sb:volume-nr></sb:series><sb:date>2001</sb:date></sb:issue><sb:pages><sb:first-page>675</sb:first-page><sb:last-page>683</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:bibliography-sec></ce:bibliography></tail></article>
